Cabaletta Bio

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Cabaletta Bio sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).

6 total trials 4 currently recruiting 1 completed early-phase tilt upper quartile by trial count

Cabaletta Bio: 6 sponsored US clinical trials, 4 recruiting.

Cabaletta Bio sponsors 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pemphigus Vulgaris, with 1 trials.

Upper-quartile sponsor footprint

Cabaletta Bio sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

6 total, page 1 of 1

RECRUITING Phase 1

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

NCT06328777
RECRUITING Phase 1

RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

NCT06121297
RECRUITING Phase 2

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

NCT06154252
RECRUITING Phase 1

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

NCT04422912
ACTIVE NOT RECRUITING Phase 1

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

NCT06359041
COMPLETED Phase 1

Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

NCT05451212

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 1

Therapeutic Areas

Pemphigus Vulgaris 1
Generalized Myasthenia Gravis (gMG) 1
Juvenile Myositis 1
Juvenile Idiopathic Inflammatory Myopathy (JIIM) 1
Juvenile Polymyositis 1
Immune-Mediated Necrotizing Myopathy 1
Anti-Synthetase Syndrome 1
Idiopathic Inflammatory Myopathy 1
Systemic Sclerosis 1
Lupus Nephritis 1

What is open in the Cabaletta Bio pipeline

4 recruiting of 6 indexed (67% open); 1 completed (17%).

Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Pemphigus Vulgaris (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Cabaletta Bio: open-pipeline peers nationwide

Peers matched on 6 registered trials and 67% open enrollment, not the therapeutic-area sidebar.

Cabaletta Bio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 234567 0%20%40%60%80% Total trials Recruiting share Cabaletta Bio23andMeAardvark TherapeuticsAbbisko Therapeutics CoAbGenomics B.V Taiwan BranchABL BioAccelerated Cure Project for Multiple SclerosisAdvanced Reconstructive Surgery AllianceAlexander B Olawaiye, MD
Cabaletta Bio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Cabaletta Bio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 6 trials (± recruiting share)

Sponsors near 67% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Cabaletta Bio page

6 registered trials is a research-attention snapshot, not an endorsement of Cabaletta Bio or any single study.

  • 4 of Cabaletta Bio's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Pemphigus Vulgaris is the condition Cabaletta Bio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pemphigus Vulgaris trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Cabaletta Bio pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.